Immuno-Oncology | Specialty

Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers

March 5th 2021

Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.

Frontline ICI Therapy Gains Traction Across NSCLC Settings

March 4th 2021

Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.

Merck Withdraws Pembrolizumab Metastatic SCLC Indication in the United States

March 2nd 2021

Merck has withdrawn pembrolizumab from the US market for the treatment of patients with metastatic small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy and at least 1 previous line of treatment.

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

March 1st 2021

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer

February 26th 2021

February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.

KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL

February 24th 2021

February 24, 2021 - The CAR T-cell product KTE-X19 continues to demonstrate durable clinical benefit in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 92%.

CAR T Explodes on the Scene in Heavily Pretreated Multiple Myeloma

February 24th 2021

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Dr. Naing on the Potential Implications of Immune-Related Adverse Effects in Cancer

February 23rd 2021

Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23rd 2021

February 23, 2021 - AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptory T-cell therapeutics.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

x